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Abstract 
Reactive oxygen species (ROS)-activated aminoferrocene-based anticancer prodrug 
candidates successfully take advantage of intrinsically high amounts of ROS in tumor 
tissues. Interestingly, the ROS-initiated activation of these prodrug candidates leads to 
formation of unstable aminoferrocene (Fc-NH2) derivatives, which decay to iron ions. The 
latter catalytically increase ROS concentration to a lethal level. In this work, we prepared 
light-controlled aminoferrocene prodrug candidates by derivatizing Fc-NH2 with an o-
nitrophenyl and an o-nitrobiphenyl photo-labile protecting group (PLPG), respectively, and 
by further conjugation to a mitochondria localization signal (MLS) peptide (Cys-D-Arg-Phe-
Lys-NH2). The resulting bioconjugates were found to be more stable and less cytotoxic, in 
the dark, towards human promyelocytic leukemia cells (HL-60) compared to Fc-NH2. Upon 
light irradiation at 355 nm, both conjugates released Fc-NH2, albeit with very different 
photolysis quantum yields. The o-nitrobiphenyl photo-cage was in fact several orders of 
magnitude more efficient than the o-nitrophenyl photo-cage in releasing Fc-NH2. This 
difference was reflected by the light irradiation experiments on HL-60 cell line, in which 
aminoferrocene conjugated with the o-nitrobiphenyl cage and the MLS displayed the highest 
phototoxicity index (2.5 ± 0.4) of all the compounds tested. The iron release assays 
confirmed the rise in iron ions concentrations upon light irradiation of both caged 
aminoferrocene derivatives. Together with the absence of phototoxicity on the non-malignant 
hTERT-immortalized retinal pigment epithelial (hTERT RPE-1) cell line, these results 
indicate catalytic generation of ROS as possible mode of action. 
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Introduction 
Aminoferrocene-based anticancer prodrug candidates recently developed by the Mokhir 
group have shown considerable selectivity towards cancer cells with IC50 values in the lower 
micromolar range (see Scheme 1A).1,2 These prodrug candidates are activated by reactive 
oxygen species (ROS) such as 1O2, O2-, HO• and H2O2, which cleave the B-C bond in an 
arylboronic acid pinacol ester linked to an aminoferrocene derivative via a carbamate 
function (see Scheme 1 for mode of action). In water, the resulting phenol is in equilibrium 
with its phenolate form, which spontaneously fragments into p-quinone methide and a 
carbamated aminoferrocene derivative via 1,6-elimination. The quinone methide is a known 
toxic compound that readily reacts with nucleophiles and attacks antioxidative defenses of 
cells by alkylating in particular glutathione (Scheme 1, Mechanism 1).3 Indeed, also 
hydroxyferrocifen – a very efficient anti-cancer drug candidate developed by the Jaouen 
group – is oxidized to quinone methide metabolites.4 Mokhir’s aminoferrocene-based 
prodrug candidates possess, however, an additional mode of action (Scheme 1, Mechanism 
2). The latter is mediated by the carbamated aminoferrocene fragment, which 
decarboxylates under physiological conditions.1,2 Most aminoferrocene derivatives are rather 
unstable since they are easily oxidized to their ferrocenium forms (Fc+),5 which in turn can 
decompose into iron ions and cyclopentadiene ligands.1 The reason behind the instability of 
aminoferrocene (Fc-NH2) or its ferrocenium form [FcNH2]+ is still speculative. Both Fc+ and 
iron ions can catalyze ROS generation elevating cellular levels of ROS to a toxic level.6,1 
Tumors generally function at a higher basal concentration of ROS than normal tissues7 and 
are already harmed by relatively small increases in ROS amount. As Mokhir’s 
aminoferrocene-based prodrug candidates are activated by ROS-induced fragmentation, 
these prodrug candidates are predominantly harming cancer cells.1,2 As a matter of fact, the 
most toxic prodrug candidate of the series has shown more than a 10-fold selectivity for 
human promyelocytic leukemia cell line (HL-60) over normal fibroblasts.1 Interestingly, the 
cytotoxicity of the aminoferrocene-based prodrug candidates correlates with their efficiency 
of ROS production in cells, showing that the aminoferrocene moiety heavily contributes to 
the observed cytotoxicity.1,2 A similar concept has also been implemented by the Jacob 
group using ROS-activated organochalcogen compounds catalyzing ROS generation.8 
Besides internal triggers such as high ROS levels, external triggers, e.g. light-activation, can 
be used to control the activity of a compound. Photosensitizers – molecules able to generate 
toxic singlet oxygen and other ROS upon light irradiation – are already being applied in the 
clinic in photodynamic therapy (PDT).9 A great number of organic photo-active compounds  
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Scheme 1. A) Activation of a previously reported aminoferrocene-based prodrug candidate by ROS. 
B) Mechanisms of cytotoxicity.1 
that are activated via cleavage of a light-sensitive bond have been reported.10,11 When it 
comes to metal complexes, some of them are inherently photo-reactive by themselves via 
light-induced redox and/or ligand exchange reactions. These changes can be exploited to 
increase the cytotoxicity of metal compounds12 or to construct metal-based photo-cages 
(e.g. for neurotransmitters).13 Encouraged by the recent use of organic photo-cages in the 
design of light-activated metal-containing prodrug candidates,14,15 we envisaged photo-
caging a simple cytotoxic ferrocenyl derivative, namely Fc-NH2 with o-nitrophenyl-based and 
o-nitrobiphenyl-based photo-labile protecting groups (PLPG) via a carbamate bond (Scheme 
2). The resulting derivatives were expected to be more stable in physiological conditions 
compared to aminoferrocene itself due to the electron-withdrawing effect of the carbamate. 
The aminoferrocene would then be liberated upon UV-A light irradiation and oxidized to its 
ferrocenium form and irons ions, which could act as ROS-generation catalysts in cancer 
cells. Furthermore, a mitochondrial localization signal (MLS) peptide (Cys-D-Arg-Phe-Lys-
NH2) was added to the photo-caged aminoferrocene bioconjugate to target mitochondria – 
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organelles where the redox balance plays an especially important role.16 Of note, the 
conjugation of photocages with targeting peptides has been realized before.15 
 
Results and discussion 
 
Synthesis and Characterization 
Aminoferrocene (Fc-NH2) was caged with an o-nitrophenyl-based photo-linker also known 
as the Dmochowski photo-labile protecting group 1.17 Interestingly, this PLPG allows for 
coupling to a further moiety such as a targeting biomolecule. Our group has previously 
reported the preparation of PLPG-containing bioconjugates of a rhenium(I) complex18 and 
Ru(II) complexes.19 This coupling procedure could be successfully applied to the photo-
caging and bioconjugation of Fc-NH2. Following this synthetic protocol, the primary amino 
group of Fc-NH2 was blocked with 1 via N-hydroxysuccinimide ester coupling to give 2 
(Scheme 2 A). The product was fully characterized by 1H- and 13C-NMR, ESI-MS, LC-MS 
and X-ray crystallography (see X-ray crystallography section). The ESI-MS spectrum (Figure 
S1) showed the expected mass at m/z = 503.3 [M+]. In the 1H-NMR of 2, the most notable 
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Scheme 2. A) Synthesis of 5: a) Fc-NH2, DIPEA, CHCl3, 62%; b) Cys-D-Arg-Phe-Lys-NH2, acetonitrile/water 1:1. B) Synthesis of 6: a) i. N,N'-disuccinimidyl carbonate, triethylamine, acetonitrile; 
ii. Fc-NH2, DIPEA, CH2Cl2, 50% over both steps; b) Cys-D-Arg-Phe-Lys-NH2, acetonitrile/PBS (pH=7.4) 2:1. DIPEA: diisopropylethylamine. 
change in shifts compared to the starting materials Fc-NH2 and 1 was observed for the 
aminoferrocene moiety (Figures S3 and S6). Indeed, both the amino group proton – now 
part of the carbamate bond – and the substituted cyclopentadienyl (Cp) ring protons shifted 
significantly downfield of about 3.5 and 0.8 ppm, respectively. The protons of the moiety 
derived from 1 were comparatively less affected (Figures S3 and S7). The protons near the 
newly formed carbamate bond shifted slightly (0.05-1 ppm) upfield. Interestingly, a slight 
doubling of peaks of the substituted Cp ring was observed in both 1H- and 13C-NMR spectra 
in CDCl3 (Figures S3, S8 and S9). Similar effects have been reported for ferrocenyl amides 
of 1-aminoferrocene-1’-carboxylic acid by Heinze and coworkers20 and were attributed to a 
hydrogen-bonded dimer formed in non-coordinating solvents. Indeed, in d8-THF, the 1H-
NMR spectrum of 2 still displayed the double signal (Figure S4), but its 13C-NMR showed 
only single peaks for the substituted Cp moiety (Figure S9). 
Likewise, Fc-NH2 was caged with an o-nitrobiphenyl based photo-linker 3 which was 
previously developed by Goeldner and coworkers (Scheme 2 B).21 We recently reported a 
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derivative of this cage to which a targeting peptide can be attached via click chemistry.22 
Here, we introduced a maleimide function to allow for coupling of thiol-containing 
biomolecules. Activation with disuccinimdyl carbonate and subsequent coupling to Fc-NH2 
gave the second caged derivative 4. The product was fully characterized by 1H and 13C NMR 
(Figures S21 and S22), IR spectroscopy, and high resolution mass spectrometry. In the 1H 
NMR spectrum, possible shifts of the proton signals belonging to the substituted Cp ring are 
not traceable since the protons of the tetraethylene glycol linker are detected in the same 
region. However, in analogy with 2 (Figure S3) and in contrast to 3 (Figure S19), the 
multiplet in that region expands down to 4.7 ppm. This indicates that attachment of Fc-NH2 
to 3 resulted in the same electronic changes due to the carbamate bond formation. 
The photo-caged aminoferrocenes 2 and 4 were then conjugated to a mitochondria 
localization signal peptide (MLS) via Michael addition of the cysteine thiol of the peptide to 
the maleimides of the PLPGs (Scheme 2). After preparative HPLC purification and 
lyophilisation, 5 and 6 were obtained as light-yellow solids. For 5, the presence of the 
desired product was confirmed by ESI-MS where peaks at m/z = 352 [M+3H]3+, 528.1 
[M+2H]2+ and 1055.4 [M+H]+ (Figure S13) were observed. As for the photo-caged 
rhenium (I) bioconjugate,15 small m/z peaks corresponding to products of photo-uncaging (o-
nitrobiphenyl cage with MLS peptide, and Fc-NH-COOH) were observed in the LC-MS 
spectra. This uncaging process happened due to the harsh ionization conditions used for 
LC-MS as uncaged complex and byproducts eluted at different times (Figures S14 and 36). 
Successful synthesis of 6 was confirmed by ESI-MS where m/z = 436 [M+3H]3+, 654 
[M+2H]2+ and 1307 [M+H]+ (Figure S24) were detected. The purities were checked by 
analytical HPLC (Figure S23). 
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X-Ray Crystallography 
Single crystals of 2 suitable for X-ray analysis were obtained by vapor diffusion 
recrystallization (see X-ray crystallographic part in the experimental section). The structure 
was solved with direct methods using SIR9733 and was refined by full-matrix least-squares 
methods on F2 with SHELXL-97 (see Table S1 in the Supporting Information). Only a few X-
ray structures of compounds consisting of 1-(2’-nitrophenyl)ethyl ester unit are known,23,24,25 
but only two of them were actually synthesized as precursors for photolabile substances.23,24 
2 crystallized in the centrosymmetric triclinic space group P-1 and is in an overall bent 
conformation, essentially like a horseshoe, where the two ends, ferrocene and maleimide, 
almost touch each other (Figure 1). Additionally, 2 forms in the solid state a dimer via two 
hydrogen bridges: The amide nitrogen N1 is in close contact with one of the maleimide 
oxygen atoms O6_$1 (-x+2, -y+2, -z) at a distance of 2.9003(15) Å and the amide of that 
molecule back binds to the original molecule to build the cyclic dimer (Figure S11). 
 
Figure 1. ORTEP representation of the crystal structure of 2. Ellipsoids were drawn at 50% 
probability. 
 
Photolysis Quantum Yields 
With the bioconjugates in hand, the next step in this study was to evaluate the photo-
uncaging of 5 and 6 by measuring their laser photolysis quantum yield in PBS (pH=7.4) at 
355 nm. The decomposition of 5 and 6 was monitored by LC-MS until 20% of the initial 
compound was photolysed (Figures S32-34). Calculated relative to the trans-to-cis 
photoisomerization quantum yield of azobenzene at this wavelength (15%),26–28 a yield of 
0.07 ± 0.02% for 5 indicates a rather inefficient photo-release process, that runs much 
slower than the photolysis of the similar Re(I) bioconjugate.15 The carbamate-based photo-
cages for amines first release the amine as a carbamate salt, which then in turn 
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decarboxylates.11 The rate of decarboxylation depends on the pKa of the amine group and a 
more acidic aromatic amine of Fc-NH2 is expected to decarboxylate slower than an aliphatic 
amine of the reported Re(I) complex. However, we monitored the disappearance of 5 rather 
than the appearance of the released Fc-NH2. Hence, the observed slower decomposition 
cannot be ascribed to the decarboxylation step. Rapid photo-uncaging of the Re analogue 
could be ascribed to the high absorptivity of the Re(I) chromophore at the irradiation 
wavelength, which could enable it to act as an “light-antenna”. Nevertheless, the photolysis 
quantum yield of 5 at 355 nm is also considerably lower than that of phosphate photo-caged 
with o-nitrophenyl group.26,28 An interference of the proximal ferrocene unit with the 
photochemistry cannot be excluded. The exact reasons, however, behind the particularly 
inefficient photo-release of Fc-NH2 from 5 are still speculative. The uncaging quantum yield 
of 6 was determined in a similar fashion. The quantum yield is with 1.8 ± 0.48% higher than 
for 5, and is accompanied by a seven-fold higher absorptivity at 355 nm compared to 5 (see 
Figure 2). The propyl-o-nitrobiphenyl cage core has previously, to the best of our knowledge, 
not been used to cage amines via carbamates. A direct comparison regarding the uncaging 
quantum yield cannot therefore be made in this case. 
5
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Figure 2. UV/Vis spectra of 5 and 6 in PBS buffer (pH=7.4). 
 
UV-A Irradiation and Iron Release 
Although a monochromatic laser setup allows for accurate determination of uncaging 
quantum yields, it is impractical for cell culture irradiation experiments. To this end, a UV-A 
reactor (Rayonet) equipped with lamps emitting in the 300-400 nm range (emission centered 
at 350 nm) was used. To find a suitable UV-A light dose for the cell irradiation experiments, 
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the more slowly uncaging 5 was photolysed under the same experimental setup as for 
cytotoxicity assays (100 μM in PBS buffer solution (pH=7.4) in a covered 96-well plate, 
30 °C). As expected from the quantum yield measurements, the photolysis of 5 proceeded 
very slowly and required a relatively high light dose to complete (18 J/cm2; Figure S31). 
Such elevated dose of UV-A light would on its own affect cell proliferation, so a maximal 
UV-A light dose safe for cells (3.3 J/cm2) was used in cytotoxicity experiments.15 Using this 
light dose, neither the light irradiation nor secondary effects, e.g. temperature changes, 
affected the cells significantly. During irradiation experiments, the formation of Fc-NH2 and 
photo-cage byproducts was detected by LC-MS for 5 only (Figure S36). This is due to the 
fact that the sample solutions were adjusted to have the same absorbance at the irradiation 
wavelength. However, 5 has a significantly lower molar absorptivity at 355 nm compared to 
6 (Figure 2). As a result, 5 was used in a considerably higher concentration and the products 
of its photolysis were easier to detect. The observation of products corresponding to the 
typical uncaging reaction are indicative of Fc-NH2 being released via the normal uncaging 
mechanism, as opposed to direct degradation of Fc-NH2. Of note, to observe the 
appearance of Fc-NH2, the samples had to be analyzed immediately after irradiation or kept 
frozen in liquid nitrogen prior to analysis due to the instability of Fc-NH2. The Fc-NH2 peak 
initially increased with the light dose, but was not observed at higher doses (Figure S32). 
The irradiation of Fc-NH2 alone demonstrated that the compound decomposed faster than 
the caged 5 released it (Figure S35). The photo-decomposition of Fc-NH2 was also followed 
by UV/Vis spectroscopy (Figure S39). At a lower irradiation dose, the UV absorbance of the 
sample actually increases in the 250-350 nm range indicating formation of Fc+, which 
absorbs stronger than ferrocene in this range.29 Yet, at higher light doses, the characteristic 
Fc transitions in the 275-500 nm range decrease and then disappear completely. 
Studies on aminoferrocene-based prodrug candidates’ decomposition have shown that such 
molecules could decay into iron ions and cyclopentadienyl ligands.1,2 The release of iron 
ions played in fact an important role in the cytotoxicity mechanism of Mokhir’s complexes as 
catalysts for ROS generation.1,2 To verify if the photo-decomposition of 5, 6 and Fc-NH2 
resulted in the same products, the iron release upon light irradiation was monitored in PBS 
buffer (pH=7.4). More specifically, the compounds were irradiated by UV-A (as described 
above for UV-A dose determination) and the amount of free iron ions was quantified by 
formation of iron(II) tris(2,2’-bipyridine) complex and monitoring its strong absorption at 
519 nm.1 The assay showed that both 5 and 6 generated iron ions upon light irradiation, but 
long irradiation times were required to free up all iron (Figures S41-43). The iron release in 
the dark was also followed for 4 h, but no significant increase in iron ions was detected 
(Figures S45 and 46). Fc-NH2, on the other hand, decomposed rapidly into iron ions even in 
11 
 
the dark. Light irradiation only slightly increased the rate of iron release (Figure S43). These 
results demonstrate that the photo-caging of Fc-NH2 succeeds in enhancing its stability in 
aqueous media at physiological pH. This effect is most likely due to decreased electron 
donation from the primary amino group, which is converted to a carbamate in 5 and 6. The 
decay into iron ions is clearly a complex multi-step process and the observed rate of 5, 6 
and Fc-NH2 photolysis is consequently not always proportional to the appearance of iron 
ions. Indeed, although 5 decomposes considerably slower than 6 (see the quantum yields 
and absorptivities above), its iron release rate is only about 2-fold slower. 
To verify that the iron ions are released as a consequence of the expected photo-induced 
nitrobenzene-uncaging reaction, 7, which lacks the nitro group necessary for uncaging, was 
synthesized (see Figure 3 for the structure of the compound and the Supporting Information 
for experimental details). As a first control, we checked the stability of 7 in d6-DMSO:D2O 
3.5:1 (v:v) by 1H NMR spectrometry over 24 h. As can be seen in Figure S27, no sign of 
decomposition was observed. The iron release of 7 relative to UV irradiation was then 
monitored like for the properly caged derivatives 5 and 6. As expected, no release of iron 
could be observed upon light irradiation (see Figure S44). Thus, the presence of the nitro 
group in 5 and 6 is necessary for the iron release. This observation supports the photo-
uncaging mechanism. As a very important note of caution, we would like to highlight that a 
few iron detection assays have been recently put into question by Burdette for failing to 
consider the stability of Fe(II) and Fe(III) ions in water and the effect of other chemicals used 
in the assay.30 In particular, the use of phosphate buffer is questionable as the solubility of 
iron phosphate salts in water is extremely low. Our control experiments, however, 
demonstrate that iron 2,2’-bipyridine complex absorbance (quantified in iron detection) is 
equivalent in PBS (pH=7.4) and MOPS (pH=7.5) buffers at relevant concentrations (Figure 
S40). While our iron release results are plausible and fit with those of Mokhir et al.,1 they 
should rather be interpreted qualitatively than quantitatively until the accuracy and precision 
of iron assays are fully validated. 
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Figure 3. Structure of compounds 7 and 8 prepared for control experiment regarding the uncaging 
mechanism and the cytotoxicity mechanism, respectively (see Supporting Information for 
experimental details). 
 
Cytotoxicity 
The light-dependent anti-proliferative effect of 5, 6 and Fc-NH2 was investigated on human 
promyelocytic leukemia (HL-60) and non-cancerous hTERT-immortalized retinal pigment 
epithelial (hTERT RPE-1) cell lines. To assess the light cytotoxicity, cells were incubated 
with the compounds for 4 h prior to irradiation. Afterwards, the cells were left to recover in 
the presence of the compounds for 46 h. Dark toxicity was determined after 50 h incubation 
time in the dark. Cell viability was quantified using the resazurin assay (6 h incubation). As 
shown in Table 1, the dark cytotoxicity of Fc-NH2 towards HL-60 was significantly decreased 
by derivatization with photo-protecting groups and peptide conjugation. Only a slight 
increase in cytotoxicity (1.3-1.5 fold) was observed for Fc-NH2 and 5 upon light irradiation on 
HL-60 cells. In the case of Fc-NH2, these results can be rationalized in terms of its instability. 
In fact, most of Fc-NH2 decomposed before the cells were irradiated (see Figure S43). The 
low cytotoxic impact of 5 can be explained by an extremely low uncaging efficiency of this 
compound. 6 is not as benign in the dark as 5, but possess an improved phototoxic index of 
about 2.5. Upon light irradiation, the IC50 value of 6 reaches the level of Fc-NH2. 
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Table 1. Cytotoxicity (IC50) of 5, 6, 8 and Fc-NH2 towards human cell lines. 
 HL-60 hTERT RPE-1 
 darka 
[µM] 
UV-Ab 
[µM] 
Phototoxic 
Index 
darka 
[µM] 
UV-Ab 
[µM] 
Phototoxic 
Index 
Fc-NH2 18.4 ± 0.1 12.1 ± 0.7 1.5 ± 0.1 42.4 ± 9.2 38.2 ± 3.1 1.1 ± 0.3 
5 72.6 ± 0.8 55.4 ± 3.9 1.3 ± 0.1 >100 >100 - 
6 40.0 ± 0.6 15.7 ± 2.8 2.5 ± 0.4 39.0 ± 1.1 37.1 ± 2.9 1.1 ± 0.1 
8c 70.1 ± 3.6 69.0 ± 2.0 1.0 ± 0.1 75.5 ± 2.2 n.d. n.d.- 
a incubated with the compounds for 56 h (including 6 h resazurin assay); b incubated with the 
compounds for 4 h prior to irradiation (10 min, 3.3 J·cm-2, UV-A reactor at 350 nm), then incubated for 
another 52 h (including 6 h resazurin assay); c 24 h resazurin assay; n.d.: not determined. 
Except for 6 in the dark, all tested iron containing compounds are less toxic towards non-
cancerous hTERT RPE-1 cells and show no effect of light-irradiation on this cell line. The 
difference is likely due to the elevated levels of ROS characteristic for tumors. This 
enhanced ROS generation pushes the ROS scavenging system of cancer cells to the limit 
and a further increase in ROS can tip the scale towards cellular death. The similar toxicity of 
6 in the dark in HL-60 and hTERT RPE-1 cells could be explained by a ROS independent 
toxicity mechanism in this case. In order to test the hypothesis of the iron mediated redox 
mechanism, the cytotoxicity of the caged aniline derivative 8 was determined (see Figure 3 
for the structure of 8 and the Supporting Information for experimental details). The uncaging 
quantum yield of 8 is with 2.9 ± 0.22% slightly higher than the one of 6. Nevertheless, the 
toxicity of 8 was found to be independent from light irradiation. Furthermore, no increased 
toxicity towards the cancer cell line HL-60 was found, compared to the hTERT RPE-1 cell 
line. Thus, the data indicate that the cytotoxicity mechanism of 5, 6 and Fc-NH2 is likely to 
involve catalytic ROS generation by the liberated iron ions, as suggested by the Mokhir 
group for their aminoferrocene-based prodrug candidates.1,2 Indeed, the IC50 values of 5, 6 
and Fc-NH2 on HL-60 cells are in the same range as those reported by the Mokhir group on 
the same cell line. 6 has in fact the IC50 value very close to that of the most toxic compound 
tested on HL-60 by Mokhir’s group (15.7 ± 2.8 vs 9 ± 2).1 All in all, the data demonstrate that 
the activity of cytotoxic aminoferrocene compounds can be efficiently controlled by a photo-
caging strategy.  
The direct quantification of the cellular uptake of our compounds remains challenging as it 
cannot be monitored by conventional methods such as fluorescence microscopy, atomic 
absorption spectrometry or inductively coupled plasma-mass spectrometry. However, 
additional indirect information could be obtained by evaluating, for example, the cellular ROS 
production, the change in the mitochondrial membrane potential or in cellular respiration. 
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Further studies are therefore required to elucidate the efficiency of targeting vectors and the 
anti-proliferative effect of 5 and 6 in more detail. 
 
Conclusion 
In this work, we have successfully prepared and characterized two light-activatable 
aminoferrocene-based prodrug candidates (5 and 6) using two different photo-cages. Upon 
UV-A light irradiation, both bioconjugates released aminoferrocene, which rapidly decayed 
into iron ions under physiological conditions. Despite this decomposition – or most likely due 
to it – aminoferrocene considerably reduced the proliferation of cancer cells (HL-60) both in 
dark and upon light irradiation. While both cages improved the stability of aminoferrocene 
and therefore attenuated its dark cytotoxicity, 6 displayed a higher uncaging efficiency, 
higher phototoxic index and lower light IC50 value compared to 5. Importantly, the absence of 
cytotoxicity upon light irradiation of 5 and 6 on non-cancerous cells contrary to cancer cells 
suggests that these compounds exploit the elevated ROS levels typical of cancer cells. Their 
mode of action is then likely based on the catalysis of ROS generation by released iron ions. 
In addition to the selectivity derived from this inherent property of the tumors, our photo-
caged aminoferrocene prodrug candidates also offer spatial and temporal control of their 
activity via light irradiation. Besides, PLPGs offer a possibility of derivatization with a 
targeting vector. We believe that this concept holds great potential, especially when 
considering the severe side-effects frequently encountered by patients undergoing 
chemotherapy. Importantly, the currently greatest shortcoming of the system, the need for 
irradiation with potentially harmful and relatively lowly tissue penetrating UV light could in 
future studies be avoided by the use of two-photon uncaging with light in the near-IR 
range.22,31 
 
Experimental Section 
 
Materials and Instruments 
Chemicals and solvents were purchased reagent grade or better from commercial suppliers 
and used without further purification unless otherwise specified. Reactions with potentially 
photo-labile components were carried out under exclusion of light. 1H and 13C NMR spectra 
were recorded with Bruker 400 and 500 spectrometers. The chemical shifts were referenced 
relative to the solvent signals. UV/Vis spectra were recorded on Varian Cary 50 Scan and 
Cary 100 spectrophotometers. ESI-MS and LC-MS were obtained with a Bruker Daltonics 
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HCT 6000 mass spectrometer. LC-MS spectra were measured on an AcquityTM from Waters 
system equipped with a PDA detector and an auto sampler using an Agilent Zorbax 300SB-
C18 analytical column (3.5 μm particle size, 300 Å pore size, 150 × 4.6 mm). The LC run 
(flow rate: 0.3 mL min–1) was performed with a linear gradient of A (distilled water containing 
0.1% v/v formic acid) and B (acetonitrile, containing 0.1% v/v formic acid); t = 0 min, 5% B; 
t = 3 min, 5% B; t = 17 min, 100% B; t = 20 min, 100% B; t = 25 min, 5% B. Analytical HPLC 
was carried out using a Macherey-Nagel EC 250/3 NUCLEOSIL 100-5 C18 column on a 
VWR Chromaster system with 5110 pump, 5210 autosampler, 5310 column oven and 5430 
diode array detector. Analytical HPLC run (flow rate1 mL/min) were performed with a linear 
gradient of A (distilled water containing 0.1% v/v TFA) and B (acetonitrile): t = 0 min, B = 5%; 
t = 18 min, B = 39%; t = 27 min, B = 100%; t = 31 min, B = 100%; t = 36 min, B = 1%; t = 
38 min, B = 1%, t = 40 min, B = 5%; t = 41 min, B = 5), unless noted otherwise. HPLC 
purification was performed on a Varian ProStar system using an Agilent PrepHT 300SB-C18 
preparative column (5 μm particle size, 300 Å pore size, 150 × 21.1 mm. Flow rate: 
20 mL min–1). The runs were performed with a linear gradient of A (distilled water containing 
0.1% v/v TFA) and B (acetonitrile (Sigma–Aldrich HPLC-grade), containing 0.1% v/v TFA), 
unless noted otherwise. Photolysis quantum yields were measured using an Edinburgh LP-
920 setup equipped with a Continuum Surelite laser (355 nm). Cell culture photo-irradiation 
and iron release assays were conducted using a Rayonet RPR-200 photochemical reactor 
using 6 bulbs (14 W each) emitting in 300–400 nm range with maximum intensity output at 
350 nm. The temperature inside the reactor was 30 °C. The light intensity was 55 W/m2, as 
determined with a X11 optometer (Gigahertz-Optik). 
 
Synthesis and Characterization 
Fc-NH2 
Aminoferrocene was prepared using a procedure previously published.32 The analytical data 
matched what that previously reported.32 
 
Compound 1 
The photolinker was synthesized following a procedure previously published.17 The 
analytical data matched what that previously reported.17 
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Compound 2 
1 (30 mg, 0.072 mmol) and aminoferrocene (15 mg, 0.072 mmol) were dissolved in dry 
chloroform (1 mL). Diisopropylethylamine (24 mg, 31 μL, 0.18 mmol) was then added to the 
mixture, which was stirred for 4 h at 35 °C. The solvent was then removed under vacuum to 
give a sticky brown solid, which was purified by column chromatography (silica gel, 
CH2Cl2/EtOAc 9:1) to afford 2 as an orange-red solid (22 mg, 62%). 
Rf = 0.86 (CH2Cl2/EtOAc 9:1). 1H NMR (500 MHz, CDCl3) δ 7.92 (d, 3J = 8.5 Hz, 1H), 7.64 
(s, 1H), 7.39 (d, 3J = 8.5 Hz, 1H), 6.67 (s, 2H), 6.29 (q, 3J = 6.5 Hz, 1H), 6.02 (s, 1H), 4.71 (s, 
2H), 4.49 (m, 1H), 4.46 (m, 1H), 4.15 (s, 5H), 3.98 (m, 1H), 1.63 (d, 3J = 6.5, 3H). 13C NMR 
(125 MHz, CDCl3) δ 170.2, 152.6, 147.0, 142.1, 139.4, 134.5, 128.6, 127.5, 125.5, 69.5, 
69.0, 64.7, 64.6, 60.9, 60.8, 40.9, 22.3, one signal coincidental or not observed. ESI-MS 
calcd. for C24H21FeN3O6 [M]+ 503.3, found 503.1. ESI-HRMS m/z calcd. for C24H21FeN3O6 
([M]+) 503.0780, found 503.0778; calcd. for C24H21FeN3O6Na ([M+Na]+) 526.0677, found 
526.0673; calcd. for C24H21FeN3O6K ([M+K]+) 542.0417, found 542.0411; calcd. for 
C19H16FeN3O6 ([M-Cp]+) 438.0389, found 438.0871; calcd. for C11H11FeNO2 ([FcNHCOOH]+) 
245.0139, found 245.0130. 
 
MLS peptide 
The peptide was prepared following a previously published general peptide synthesis 
procedure.33 
ESI-MS m/z calcd. for C24H41N9O4S ([M+H]+) 552.3, found 552.3; calcd. for C24H42N9O4S 
([M+2H]2+) 276.7, found 276.6. 
 
Compound 5 
2 (20 mg, 40 μmol) and MLS peptide (35 mg, 40 μmol) were first pre-dissolved in DMSO 
(30 μL) and then in acetonitrile/water mixture 1:1 (1 mL). The reaction mixture was stirred 
overnight at room temperature. The solvents were removed by lyophilization and the 
compound was purified by preparative HPLC to obtain it as a light-yellow solid. Preparative 
HPLC run: t = 0 min, 5% B; t = 25 min, 100% B; t = 30 min, 100% B; t = 32 min, 5% B; tR 
=18.6 min. 
ESI-MS m/z calcd for C48H62FeN12O10S ([M+H]+) 1055.4, found 1055.4; calcd for 
C48H63FeN12O10S ([M+2H]2+) 528.2, found 528.1; calcd for C48H64FeN12O10S ([M+3H]3+) 
352.3, found 352.2. UV absorption (PBS buffer, pH=7.4): ε(λ=264 nm) =13037 M-1cm-1; 
ε(λ=355 nm) = 1235 M-1cm-1. 
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Compound 4 
Under an atmosphere of N2, N,N'-disuccinimidyl carbonate (70.3 mg, 0.275 mmol) was 
added to a solution of 3 (see Supporting Information; 82.9 mg, 0.157 mmol) in acetonitrile 
(2 mL). Triethylamine (76.6 µL, 55.6 mg, 0.549 mmol) was added to the stirred suspension, 
and stirring was continued for 6.5 h. All volatiles were removed on a rotary evaporator. The 
remaining residue was taken up in EtOAc and washed with 0.1 M NaHCO3. The layers were 
separated and the aqueous layer was twice extracted with EtOAc. The combined organic 
layers were washed with brine, dried (Na2SO4), filtered and concentrated. Column 
chromatography (silica gel, CH2Cl2/EtOAc 8:2) yielded the intermediate active ester of 3 as a 
yellow oil (55 mg, would correspond to 52%), which was directly used in the next reaction 
step. 
The active ester of 3 (21 mg, would correspond to 31 µmol), aminoferrocene (8.2 mg, 
41 µmol) and diisopropylethylamine (6.5 mg, 8.5 µL, 50 µmol) were dissolved in dry CH2Cl2 
(4 mL) and stirred under exclusion of light for 15 h at rt. Saturated NH4Cl solution was added 
and the mixture extracted with CH2Cl2 (3x). The combined organic layers were dried 
(MgSO4), filtered and concentrated. Purification by column chromatography (silica gel, 
CH2Cl2/MeOH 200:198:2) gave pure 4 as brown viscous oil (23 mg, 96% for 2nd step, 50% 
over both steps). 
Rf = 0.46 (CH2Cl2/MeOH 95:5). IR (neat) 3095(w), 2874 (w), 1702 (s), 1604 (m), 1515 (s), 
1346 (m), 1232 (m), 1103 (m), 1074 (m), 932 (w), 824 (s), 695 (m) cm–1. 1H NMR (500 MHz, 
CDCl3) ∂ 7.85 (d, J = 7.9 Hz, 1 H), 7.69–7.42 (m, 4 H), 7.02 (d, J = 7.9 Hz, 2 H),6.67 (s, 2 H), 
5.72 (bs, 1 H), 4.73–3.30 (m, 28 H), 1.41 (d, J = 6.5 Hz, 3 H). 13C NMR (125 MHz, CDCl3): ∂ 
170.6, 159.5, 153.2, 149.0, 145.4, 138.0, 134.1, 131.5, 128.5, 125.9, 125.4, 125.0, 115.2, 
70.9, 70.7, 70.6, 70.1, 69.6, 69.5, 68.8, 67.8, 67.6, 64.7, 60.6, 37.1, 33.3, 17.4, one signal 
coincidental or not observed. ESI-MS m/z 778.2 (100, [M+Na]+), 755.2 (49, [M]+), 389.1 (88, 
[M+Na]2+). HRMS m/z calcd. for C38H41N3O10 ([M]+) 755.21358, found 755.20277. 
 
Compound 6 
4 (20 mg, 26 µmol) and MLS peptide (15 mg, 26 µmol) were dissolved in a mixture of 
acetonitrile (2 mL) and PBS buffer (1 mL). The solution was stirred for 7 h at rt. The solvents 
were removed by lyophilization. Purification by preparative HPLC (20 mL/min, H2O + 0.1% 
TFA : acetonitrile = 0 min: 95:5, 27 min: 35:65, 31 min: 0:100, 33 min: 0:100, 36 min: 95:5, 
37 min: 95:5, tR = 13 min) gave pure 6 as a brown solid. 
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ESI-MS m/z 654 (100, [M+2 H]2+), 436 (40, [M+3 H]3+), 1307 (8, [M+H]+). tR = 22.6 min 
(HPLC analytical gradient). UV absorption (PBS buffer, pH=7.4): ε(λ=355 nm) = 
8732 M-1cm-1. 
 
X-Ray Crystallography 
Crystals were grown by vapour diffusion of cyclohexane into a solution of 2 in methylene 
chloride.34 Crystallographic data were collected at 183(2) K with Mo Kα radiation (λ = 
0.7107 Å) that was graphite-monochromated on an Oxford Diffraction CCD Xcalibur system 
with a Ruby detector. Suitable crystals were covered with oil (Infineum V8512, formerly 
known as Paratone N), placed on a nylon loop that is mounted in a CrystalCap Magnetic™ 
(Hampton Research) and immediately transferred to the diffractometer. The program suite 
CrysAlisPro was used for data collection, multi-scan absorption correction and data 
reduction.35 The structure was solved with direct methods using SIR9736 and was refined by 
full-matrix least-squares methods on F2 with SHELXL-97.37  
 
Photophysical Characterization 
Photolysis quantum yield 
20 mM DMSO stock solutions of 5 and 6 were diluted in phosphate buffer (pH=7.4) to obtain 
optical density at 355 nm (OD(λ = 355 nm)) of 0.2. Fluorescence cuvette (1 cm x 0.2 cm, 
Hellma 105.250-QS with 100 μL of solution was irradiated at 355 nm using an Edinburgh LP-
920 laser flash photolysis setup equipped with a Continuum Surelite Nd:YAG laser, 
frequency tripled to generate light with a wavelength of 355 nm. The laser beam was slightly 
misaligned to obtain a suitable irradiation power. A fresh aliquot of solution was used for 
each irradiation. After a certain number of laser shots the solutions were transferred to 
amber HPLC vials with a 200 μL inlet. The vials were then kept frozen in liquid nitrogen and 
unfrozen 2 min prior to analysis by LC-MS due to the instability of released aminoferrocene. 
The peak corresponding to 5 or 6 was integrated and the percentage of remaining 
compound (calculated from the peak area) was plotted against the number of laser shots. 
The experiment was continued until the number of laser shots that decomposed 20% of 5 or 
6 was reached. At less than 20% conversion, the photolysis curve could be fitted by a simple 
linear regression. The slope of the linear fit  was then used to calculate the 
photolysis quantum yield by comparing it to the quantum yield of azobenzene 
photoisomerization. For that, trans-azobenzene was dissolved in methanol to obtain OD(λ = 
355 nm) = 0.2 and irradiated in the same conditions as 5 and 6. The conversion of 
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azobenzene was monitored by following the UV/Vis absorbance at 355 nm. The irradiation 
was continued until 20% of azobenzene had isomerized. The percentage of remaining 
amount of trans-azobenzene was then plotted versus the irradiation dose (measured in 
number of laser shots) and fitted by a linear curve as for 5 and 6 (see above). The slope of 
azobenzene curve  was used to calculate the photolysis quantum yield of 5 or 6 
( ) using the following equation: 
 
where  is the quantum yield of azobenzene trans-cis isomerization at 355 nm 
(15%), and  are the amounts (in mol) of the respective compounds before irradiation. At 
least three independent sets of experiments were averaged to obtain the single-photon 
uncaging quantum yields. 
 
Photolysis in UV reactor 
To estimate the UV-A dose needed for 5 uncaging in cells, 20 mM DMSO stock solution of it 
was diluted with PBS buffer (pH=7.4) to obtain a final concentration of 100 μM (highest 
concentration used in cytotoxicity experiments). The solution was pipetted in 100 μL portions 
on a 96-well plate (used for cytotoxicity experiments) and irradiated in the UV reactor with 
different light doses. The solution composition was analyzed by LC-MS immediately after 
irradiation. The relative concentration of the photolysed compound was calculated from the 
area of the corresponding LC-MS peak. Percentage of remaining compound vs. the 
irradiation dose could be fitted by a single exponential (first order kinetics law): 
 
where  is the initial concentration,  is the rate constant and  is the irradiation dose. The 
same procedure was applied for aminoferrocene to monitor its decomposition during UV-A 
irradiation. 
 
Iron release 
Release of iron ions from Fc-NH2, 5, 6 and 7 was monitored using a procedure adapted from 
Mokhir’s work.1 More specifically, the compound of interest (5 μL, 4 mM DMSO stock 
solution) was diluted in PBS (pH=7.4, 175 μL). The concentration of iron ions was then 
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detected by addition of Na2S2O4 (10 μL, 0.8 M in water) and 2,2’-bipyridine (10 μL, 12 mM in 
DMF:water 1:1), which forms iron(II) tris(2,2’-bipyridine) complex. The amount of formed 
complex was quantified by observing its strong absorbance at 509 nm. The experiments 
were conducted in a 96-well plate using a Spectramax M2e microplate reader (Molecular 
Devices). 
 
Cell Culture 
The human promyelocytic leukemia cells (HL-60) were cultured in RPMI (Gibco) 
supplemented with 20% heat inactivated fetal calf serum (Gibco), 100 U/mL penicillin, 
100 μg/mL streptomycin at 37 °C and 5% CO2. The hTERT-immortalized retinal pigment 
epithelial cell line (hTERT RPE-1) was maintained in DMEM (Gibco) supplemented with 10% 
FCS (Gibco), 100 U/mL penicillin, 100 μg/mL streptomycin at 37 °C and 5% CO2. 
 
Photo-toxicity studies 
Photo-toxicity studies were performed on two different cell lines, namely HL-60 and hTERT 
RPE-1, by a fluorometric cell viability assay using resazurin (Promocell GmbH). Briefly, one 
day before treatment, cells were plated in triplicates in 96-well plates at a density of 
4 × 103 cells/well in 100 μL. Cells were then treated with increasing concentrations of the 
complexes for 50 h. For light toxicity measurements, the cells were irradiated 4 h after 
beginning of the treatment for 10 min at 350 nm (3.3 J/cm2) and then placed back in the 
incubator in the dark for the remaining 44 h. The cell medium was not replaced. After 
treatment, resazurin (0.2 mg/mL final concentration) was added to the 200 μL. After 6 h of 
incubation at 37 °C (24 h for 8), the fluorescence of the highly red fluorescent resorufin 
product was quantified at 590 nm emission with 540 nm excitation wavelength in a 
SpectraMax M5 microplate reader. 
 
Associated Content 
The Supporting Information is available free of charge on the ACS Publication website at 
DOI: 10.1021/acs.inorg-chem.XXXXXX. 
Synthetic procedures for precursors and control compounds; NMR spectra; mass spectra; 
UV/Vis spectra; photolysis plots; iron release plots; crystallographic table. 
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Synopsis: In this article, the selective photo-release in living cells of a cytotoxic 
organometallic complex, namely aminoferrocene (Fc-NH2) from two different bioconjugates 
containing a mitochondria targeting peptide (MLS) is presented. 
